ArticleTanaffos2025
Invasive Pulmonary Aspergillosis and Tuberculosis after COVID-19.
Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary tuberculosis (TB) and invasive aspergillosis are distinct infectious diseases that rarely coexist in the same patient. The concurrent occurrence of these infections presents diagnostic and therapeutic challenges, resulting in complex clinical presentations and potentially adverse outcomes. We present a case report highlighting the diagnostic process, management strategies, and pertinent literature regarding the simultaneous occurrence of pulmonary TB and aspergillosis in a patient following COVID-19 infection. Case Presentation: A 55-year-old male with a history of occupational exposure as a farmer and welder presented with a complex medical condition. He had a previous COVID-19 infection and was hospitalized for three weeks, receiving appropriate treatment. Subsequently, he developed dyspnea and bilateral pleural effusion and underwent treatment with broad-spectrum antibiotics. Further investigations revealed consolidation in the left upper lobe, and biopsy confirmed the presence of Aspergillus species. The patient received voriconazole treatment for several months, but minimal improvement was observed. Recurrent hemoptysis prom pted bronchoscopy, which showed positive results for acid-fast bacilli smear and TB PCR testing, indicating concomitant pulmonary TB. Anti-tuberculosis treatment was initiated alongside ongoing management for aspergillosis. Conclusion: This case report ill ustrates the diagnostic and therapeutic complexities associated with the simultaneous occurrence of pulmonary TB and aspergillosis in a patient following COVID-19 infection. Clinicians should maintain a high index of suspicion for dual infections in similar clinical scenarios. Prompt recognition, accurate diagnosis, and individualized treatment strategies are crucial for optimal patient management. Further research is warranted to enhance our understanding of this unique clinical entity and improve patient outcomes.
Indexed as
Identifiers
42027970PMC13102072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.